Literature DB >> 8685891

Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine.

A Vaccari1, P L Saba, S Ruiu, M Collu, P Devoto.   

Abstract

Acute intoxication and chronic therapy with the alcohol consumption deterrent dithiocarbamate disulfiram have been associated with several neurological complications perhaps involving the impairment of neurotransmitter pathways. In this study we have tested the hypothesis that dopaminergic malfunction is a critical component in disulfiram-evoked neurotoxicity. Disulfiram antagonized the in vitro striatal binding of [3H]tyramine, a putative marker of the vesicular transporter for dopamine, and the uptake of [3H]dopamine into striatal synaptic vesicles, with inhibitory constants (Ki) in the range of reported blood dithiocarbamate levels in treated alcoholics. Furthermore, disulfiram provoked a loss of radioactivity from [3H]dopamine-preloaded striatal vesicles, when added directly to the incubation mixture. Several metal-containing fungicide analogs were also potent displacers of specifically bound [3H]tyramine. Diethyldithiocarbamate (DDC), the major metabolite of disulfiram, had none of these effects. The intraperitoneal injection of a high dose of disulfiram and DDC into rats, mimicking acute intoxication, induced in vivo overflow of striatal dopamine from both a reserpine-sensitive (vesicular) and an alpha-methyl-p-tyrosine-sensitive (cytoplasmic) pool. The vesicular component of in vivo dopamine release resulted mainly from a direct activity of disulfiram, on the organelles (interaction with the carrier for dopamine plus membrane permeabilization) and indirectly through the mediation of serotonergic 5-HT3 receptors. DDC acted poorly at the vesicle membrane, and the in vivo releasing effect of dopamine was only partially prevented by the inhibition of 5-HT3 receptors, thus suggesting the role of additional mechanisms. It is concluded that disulfiram intoxication may acutely disrupt dopamine balance, an effect probably underlying some of the central neurotoxic, extrapyramidal symptoms associated with dithiocarbamate overdose.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8685891     DOI: 10.1006/taap.1996.0147

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  17 in total

1.  Disulfiram effects on responses to intravenous cocaine administration.

Authors:  Jennifer R Baker; Peter Jatlow; Elinore F McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2006-09-18       Impact factor: 4.492

2.  Functional neural changes following behavioral therapies and disulfiram for cocaine dependence.

Authors:  Elise E DeVito; Guangheng Dong; Hedy Kober; Jiansong Xu; Kathleen M Carroll; Marc N Potenza
Journal:  Psychol Addict Behav       Date:  2017-07-17

Review 3.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

4.  Delirium-associated disulfiram and ethanol interactions.

Authors:  Hasan Mirsal; Irem Yalug; Devran Tan; Theodore A Stern; Ayhan Kalyoncu; Ozkan Pektas; Gamze Erdogan; Mansur Beyazyürek
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 5.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 6.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

8.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

Review 9.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

10.  Disulfiram enhances subjective effects of dextroamphetamine in humans.

Authors:  Mehmet Sofuoglu; James Poling; Andrew Waters; Andrew Sewell; Kevin Hill; Thomas Kosten
Journal:  Pharmacol Biochem Behav       Date:  2008-04-04       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.